President, Oncology

Associate Director, Statistical Programming

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Corcept submits relacorilant marketing authorization application to EMA

Corcept Therapeutics Inc - terminates distribution agreement with Optime Care - SEC filing

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Medical Science Liaison/Sr. Medical Science Liaison, Oncology

Corcept Therapeutics is a leading pharmaceutical company focused on the research and development of cortisol modulators. The Oncology Medical Science Liaison (MSL) role involves engaging with thought leaders in oncology, educating healthcare professionals about cortisol modulation, and supporting clinical trials and scientific communications.

Medical Science Liaison/Sr. Medical Science Liaison, Oncology - New England Region

Associate Director, Talent Acquisition

Senior Director Human Resources

Medical Science Liaison

Senior Medical Science Liaison

Sign up with Google

Sign in with Google